Last reviewed · How we verify
Nivolumab + Relatlimab
Nivolumab and relatlimab together block two immune checkpoints (PD-1 and LAG-3) to enhance T-cell activation and anti-tumor immunity.
Nivolumab and relatlimab together block two immune checkpoint pathways (PD-1 and LAG-3) to enhance anti-tumor T-cell activity. Used for Melanoma (unresectable or metastatic), Melanoma (adjuvant treatment).
At a glance
| Generic name | Nivolumab + Relatlimab |
|---|---|
| Also known as | Opdualag, OPDUALAG, Relopduo, BMS-986213 |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Drug class | Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination) |
| Target | PD-1 and LAG-3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, preventing immune suppression. Relatlimab is a LAG-3 inhibitor that blocks LAG-3, another inhibitory checkpoint on T cells. Together, this dual checkpoint blockade removes multiple brakes on the immune system, allowing T cells to recognize and attack cancer cells more effectively.
Approved indications
- Melanoma (unresectable or metastatic)
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
Common side effects
- Fatigue
- Diarrhea
- Rash
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Nausea
Key clinical trials
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (PHASE2)
- Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (PHASE1, PHASE2)
- Pan Tumor Rollover Study (PHASE2)
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study (PHASE2, PHASE3)
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nivolumab + Relatlimab CI brief — competitive landscape report
- Nivolumab + Relatlimab updates RSS · CI watch RSS
- H. Lee Moffitt Cancer Center and Research Institute portfolio CI